Shares of PepsiCo rose nearly 2 percent Thursday, after the beverage maker reported better-than-expected third quarter profits. » Read More
Accenture shares jumped Thursday after it reported earnings above estimates, helped by new bookings and expansion in profit margins. » Read More
Jim Cramer says when these two elements occur for a stock, the bulls will begin to dance.
Investor jitters about a softer-than-expected game allocation for Wynn Resorts' newest Macau casino-resort property sent the stock lower.
Jim Cramer shares his methodology on how he picks a stocks and when to pull the trigger.
U.S. Steel is now up more than 200% on the year. And no one has been caught more by surprise than the analysts covering the name.
Hewlett Packard Enterprise bounced after a report that some of its assets may be an acquisition target for private equity firms.
The economy is growing at a much slower pace than expected, but certain types of stocks have a history of thriving in such mediocre environments.
Jim Cramer said Amazon was "the worst" out of the four major "gauntlet" companies that reported quarterly earnings this week.
Newell Brands stock is rose nearly 7 percent after the company posted better-than-expected earnings.
Oil giants ExxonMobil and Chevron took some major hits in Q2, but here's what happens next.
JPMorgan upgraded Dow Chemical to outperform, as global demand for the chemical company looked better than expected post-Brexit.
Expedia shares dropped nearly 3 percent Friday after the company missed revenue estimates for the second quarter.
Seres Therapeutics shares plummeted more than 76 percent after its drug for preventing a bacterial infection of the large intestine failed.
Vanguard shuts new investors out of dividend growth fund, as market shows signs pace of dividends won't hold up.
Goldman Sachs just downgraded its rating for Ford Motor to neutral from buy.
While 2016's anemic growth level isn't an automatic disqualifier for an interest rate increase, the bar just got a little higher.
"Halftime Report" trader Jon Najarian bought Merrimack Pharmaceuticals for his CNBC PRO model portfolio, which is up 15 percent on the year.
Get the best of CNBC in your inbox